Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 8/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 8/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 8/20 | 0.65 |
| ▸ | MAOA | P21397 | 10/20 | 0.58 |
| ▸ | MAOB | P27338 | 10/20 | 0.58 |
| ▸ | NISCH | Q9Y2I1 | 9/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955429 | 0.90 | MAOA (0.62) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| Hydrochloric Acid SCHEMBL955415 | 0.89 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL954313 | 0.86 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL953107 | 0.86 | MAOA (0.60) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| Tolazoline SCHEMBL4629750 | 0.85 | TAAR1 (0.68) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL953104 | 0.85 | ADRA2A (0.65) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| Hydrochloric Acid SCHEMBL958483 | 0.85 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| Hydrochloric Acid SCHEMBL953199 | 0.85 | ADRA2A (0.64) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| SCHEMBL953868 | 0.84 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CMAOAMAOB | |
| Hydrochloric Acid SCHEMBL953120 | 0.84 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | claimed |
| EP-3239231-B1 | METHOD FOR MANUFACTURING A CROSS-LINKABLE NITRILE RUBBER COMPOSITION AND CROSS-LINKED RUBBER PRODUCT | ZEON CORP (JP) | 2020-09-09 | — | — | EP | disclosed |
| CN-107406630-B | Nitrile rubber composition and rubber crosslinked product | 日本瑞翁株式会社 | 2019-12-03 | — | — | CN | disclosed |
| CN-107001720-B | Method for producing crosslinkable nitrile rubber composition, and rubber crosslinked product | 日本瑞翁株式会社 | 2019-12-03 | — | — | CN | disclosed |
| CN-110461892-A | Nitrile group-containing copolymer rubber | ZEON CORP | 2019-11-15 | — | — | CN | disclosed |
| CN-110431172-A | The manufacturing method of the nitrile rubber containing carboxyl | ZEON CORP | 2019-11-08 | — | — | CN | disclosed |
| CN-110431184-A | Bridging property rubber composition and rubber cross object | ZEON CORP | 2019-11-08 | — | — | CN | disclosed |
| CN-110402259-A | Nitrile group-containing copolymer rubber | ZEON CORP | 2019-11-01 | — | — | CN | disclosed |
| CN-104854183-B | Nitrile rubber composition and rubber crosslinked material | 日本瑞翁株式会社 | 2019-08-20 | — | — | CN | disclosed |
| CN-107001715-B | Nitrile rubber composition, latex composition of highly saturated nitrile rubber, and rubber crosslinked product | 日本瑞翁株式会社 | 2019-08-13 | — | — | CN | disclosed |
| CN-101134718-B | Method for synthesizing black nightshade aldehyde | YAN AN CHANGTAI PHARMACEUTICAL CO LTD | 2010-12-22 | — | — | CN | disclosed |
| EP-1981497-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-22 | — | — | EP | disclosed |
| CN-101134718-A | Method for synthesizing black nightshade aldehyde | YANI AN CHANGTAI PHARMACEUTICA (CN) | 2008-03-05 | — | — | CN | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085557-A2 | USE OF SUBSTITUTED 2-IMIDAZOLE OF IMIDAZOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | WO | disclosed |
| CN-1039264-C | Electrolytic solution and electrochemical element prepared therefrom | SANYO CHEMICAL IND LTD (JP) | 1998-07-22 | — | — | CN | disclosed |
| CN-1117323-A | Electrolytic solution and electrochemical element prepared therefrom | SANYO CHEMICAL IND LTD (JP) | 1996-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197621-A1 | Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives | GPR119, PER2, MTNR1B | ADRA2A 71/4885ADRA2B 77/4885ADRA2C 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.